Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • Safety Mirrors Market Size Exceed ,187.90 Thousand by 2030
    Safety Mirrors Market Size Exceed $81,187.90 Thousand by 2030 World News
  • Wearwell® Introduces Diamond-Plate Modular Rubber Flooring
    Wearwell® Introduces Diamond-Plate Modular Rubber Flooring Business
  • Becker Microbial Products Acquired by Founders of Proventus Bioscience
    Becker Microbial Products Acquired by Founders of Proventus Bioscience Business
  • War Day 122: war diaries w/Advisor to Ukraine President, Intel Officer @Alexey Arestovych & #Feygin
    War Day 122: war diaries w/Advisor to Ukraine President, Intel Officer @Alexey Arestovych & #Feygin World News
  • War Day 103: war diaries w/ Advisor to Ukraine President, Intel Officer @Alexey Arestovych & #Feygin
    War Day 103: war diaries w/ Advisor to Ukraine President, Intel Officer @Alexey Arestovych & #Feygin World News
  • Perishable Goods Transportation Market Size, Share And Growth Analysis For 2024-2033
    Perishable Goods Transportation Market Size, Share And Growth Analysis For 2024-2033 World News
  • Giatec® Launches an Accelerated International Expansion in Partnership With Heidelberg Materials
    Giatec® Launches an Accelerated International Expansion in Partnership With Heidelberg Materials Business
  • Madhya Pradesh Tourism shone at The 46th session of the UNESCO World Heritage Committee
    Madhya Pradesh Tourism shone at The 46th session of the UNESCO World Heritage Committee World News
New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With Progeria

New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With Progeria

Posted on March 15, 2023 By NewsEditor
New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With ProgeriaNew Progerin Biomarker Predicts Survival Benefits of Treatment in Children With ProgeriaBiomarker has future applications in new drug candidate identification and could be used in broader cardiovascular and aging-related research.

New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With Progeria
PRF Logo

The Progeria Research Foundation logo

PEABODY, Mass., March 15, 2023 (Newswire.com) - A newly developed progerin biomarker indicates long-term benefit of treatment in children with Progeria is greater than previously determined, according to a study in an advanced online publication in the journal Circulation today. The study, led by Progeria Research Foundation (PRF) co-founder and Medical Director Dr. Leslie Gordon, found that lower progerin levels in the blood samples reflected survival benefit, and a longer duration of time spent on lonafarnib (Zokinvy™) treatment was associated with an even greater increase in life expectancy than previously understood. 

Progerin is the toxic protein that causes Progeria, an ultra-rare, fatal pediatric rapid-aging disease. Progerin is found in all people but is generated at much higher levels in children and young adults with Progeria. With this new biomarker blood test, researchers can now measure the progerin level in any person at any given time—helping scientists understand how treatments are affecting clinical trial participants after only a few months on treatment and at multiple points along each clinical trial. To better understand progerin's connection to adult heart disease and the general aging process, additional studies will be necessary.

The progerin biomarker can optimize the clinical trial process by providing early information about the effectiveness of progerin-targeted treatments as a lead-in to clinical measures that can demonstrate changes later in the course of therapy. This may provide the opportunity to detect treatment benefits as early as four months after starting treatment, or stop a treatment that may not be beneficial and avoid unnecessary treatment side effects.

The study used data from the PRF International Patient Registry and blood samples from the PRF Cell and Tissue Bank, which contains samples donated from the clinical trials co-coordinated by PRF and Boston Children's Hospital (BCH). In patients with Progeria, lonafarnib (Zokinvy) lowered progerin levels by about 35 - 62 percent for as long as the children stayed on the drug. The longer a child stayed on the drug, the greater the survival benefit from being on therapy. Life expectancy for patients on treatment for 10 years was estimated to increase by almost 5 years. 

PRF's next step is to submit the biomarker data to the FDA for their critical evaluation as a validated test that can be used for measuring treatment effects and for new drug approvals.

"Measuring this new progerin biomarker from a blood sample means we can move faster towards finding better treatments and the cure for children with Progeria," said Dr. Leslie Gordon, The Progeria Research Foundation's co-founder and Medical Director. "Future treatment strategies that we are developing for Progeria, including small molecules, RNA therapeutics and DNA base editing, will all benefit greatly from this discovery." 

"We're thrilled that this study data estimates more than a 35% increase in lifespan for those who've taken lonafarnib for 10 years," said Audrey Gordon, Executive Director of The Progeria Research Foundation. "Every day, we at PRF are working toward our mission of finding new treatments and the cure. Today's announcement marks another major step closer to that goal."

"After conducting Progeria-related clinical trials at Boston Children's Hospital, where we've enrolled children from over 20 countries, having a biomarker is an exciting milestone," said Dr. Monica Kleinman, Principal Investigator for the Progeria clinical trials at Boston Children's Hospital. "We hope that following progerin levels gives us an earlier indication as to whether a trial treatment is working for children with this ultra-rare disease." 

About The Progeria Research Foundation

The Progeria Research Foundation (PRF) was established in 1999 by the family of Sam Berns, a child with Progeria. Within four years of its founding, the PRF Genetics Consortium discovered the Progeria gene, a collaboration led by Dr. Francis Collins, White House Science Advisor and former Director of the National Institutes of Health (NIH). As of 2007, PRF has funded and co-coordinated all Progeria clinical trials conducted at Boston Children's Hospital and supports scientists who conduct Progeria research worldwide. PRF's International Patient Registry includes over 370 children with Progeria in 70 countries. 

PRF is the only nonprofit organization solely dedicated to finding treatments and the cure for Progeria and its aging-related conditions, including heart disease. The organization fills a void, putting these children and Progeria at the forefront of scientific efforts. For more information and to support PRF's mission, please visit www.progeriaresearch.org. 

Contact Information:
Eleanor Maillie
Communications Manager, PRF
[email protected]
978.879.9244


Original Source: New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With Progeria

The post New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With Progeria first appeared on Social Gov.

Business

Post navigation

Previous Post: Industry Leaders Launch NeXus Digital Group
Next Post: Dynamic Media Introduces Comprehensive 2023 Background Music Buyer’s Guide

Related Posts

  • Medidex, Inc. Expands MedManage to Support Animal Shelters with New Tailored Service Line
    Medidex, Inc. Expands MedManage to Support Animal Shelters with New Tailored Service Line Business
  • Managing Hard Waste in Multi-Unit Developments
    Managing Hard Waste in Multi-Unit Developments Business
  • Population Health Management Market Size, Share, Revenue, Trends And Drivers For 2023-2032
    Population Health Management Market Size, Share, Revenue, Trends And Drivers For 2023-2032 Business
  • WASTELINQ Acquires BlazeIT
    WASTELINQ Acquires BlazeIT Business
  • ActualMeds Joins Influential Pharmacy Health Information Technology Collaborative
    ActualMeds Joins Influential Pharmacy Health Information Technology Collaborative Business
  • Investment Opportunities and Future Growth Prospects in Genetic Testing Market
    Investment Opportunities and Future Growth Prospects in Genetic Testing Market Business
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
« Aug    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • BusinessCardDesigners.com Launches Custom Business Card StudioSeptember 21, 2025
  • BioVeritas to Speak at Argus North American Biofuels, LCFS & Carbon Markets SummitSeptember 21, 2025
  • Fibank is the Best Bank for Customer Experience in Bulgaria according to EuromoneySeptember 20, 2025
  • Most American Voters Would Accept U.S.-Backed Israeli-Palestinian PeaceSeptember 20, 2025
  • Libertine forms joint ventures in Saudi Arabia and Hong Kong to commercialise intelliGEN linear generatorsSeptember 19, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • War Day 232: war diaries w/Advisor to Ukraine President, Intel Officer @Alexey Arestovych & #Feygin
    War Day 232: war diaries w/Advisor to Ukraine President, Intel Officer @Alexey Arestovych & #Feygin World News
  • Spray Performance Calculations and Tradeoffs
    Spray Performance Calculations and Tradeoffs Aviation
  • FAA International Flight Test Demonstration Takes Off
    FAA International Flight Test Demonstration Takes Off Aviation
  • Secretary Blinken’s Meeting with Tajikistan Foreign Minister Muhriddin
    Secretary Blinken’s Meeting with Tajikistan Foreign Minister Muhriddin World News
  • Space Force Association Announces General B. Chance Saltzman as Keynote Speaker at Spacepower Conference 2025
    Space Force Association Announces General B. Chance Saltzman as Keynote Speaker at Spacepower Conference 2025 Aviation
  • Password Policy Enforcement Software Market Will Rise at A CAGR of 10.5%; Industry Size, Demand & Trends Analysis 2028
    Password Policy Enforcement Software Market Will Rise at A CAGR of 10.5%; Industry Size, Demand & Trends Analysis 2028 World News
  • A Heartfelt Tale of Teenage Romance and Family Dynamics
    A Heartfelt Tale of Teenage Romance and Family Dynamics World News
  • Opportunities and Challenges for Traders in Argentina
    Opportunities and Challenges for Traders in Argentina World News
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .